4//SEC Filing
Landis John B. 4
Accession 0001562180-22-001420
CIK 0001314102other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 4:54 PM ET
Size
11.4 KB
Accession
0001562180-22-001420
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Exercise/Conversion
Common Stock
2022-02-09+2,500→ 8,400 total - Exercise/Conversion
Restricted Stock Units
2022-02-09−2,500→ 0 totalExercise: $0.00→ Common Stock (2,500 underlying) - Award
Restricted Stock Units
2022-02-09+3,000→ 3,000 totalExercise: $0.00→ Common Stock (3,000 underlying) - Award
Stock Option (Right to Buy)
2022-02-09+11,000→ 11,000 totalExercise: $10.13From: 2023-02-09Exp: 2032-02-09→ Common Stock (11,000 underlying)
Footnotes (2)
- [F1]Fully vested on the one-year anniversary of the grant date.
- [F2]Will fully vest on the one-year anniversary of the grant date.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001477283
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 4:54 PM ET
- Size
- 11.4 KB